辉瑞和生物科技公司针对XFG亚变异株开发的最新COVID-19疫苗已获美国批准用于2026-27年季节，但澳大利亚迄今尚未注册该疫苗1。这反映出澳大利亚在疫苗审批方面相比其他国家存在明显滞后1。
澳大利亚已于2025年末注册并在12月提供了针对LP.8.1亚变异株的疫苗，莫德纳的同类疫苗也已完成注册1。传染病专家保罗·格里芬指出，澳大利亚更新COVID-19疫苗的速度落后于某些国家1。
澳大利亚作为相对较小的市场，在获取新疫苗方面不总是优先于美国和欧洲等地1。此外，阿斯利康已确认无计划为2026-27年季节发布COVID-19疫苗1。
Pfizer and BioNTech's latest COVID-19 vaccine, formulated to target the XFG subvariant, has received approval in the United States for the 2026-27 season, yet Australia has not registered the vaccine.1 While Australia approved and began offering an LP.8.1-adapted vaccine in late 2025 and December respectively,1 infectious disease expert Paul Griffin noted that Australia's pace of updating COVID-19 vaccines lags behind certain other countries.1 Moderna's LP.8.1 vaccine has also been registered in Australia.1
Australia's position as a comparatively smaller market means it does not always receive priority for new vaccine releases compared to larger economies such as the United States and Europe.1 AstraZeneca has confirmed it has no plans to release a COVID-19 vaccine for the 2026-27 season.1 Experts have recommended optimizing approval processes to enable faster deployment of vaccines that match the virus's evolving strain landscape.1
评论
还没有评论，欢迎留下第一条。